Related references
Note: Only part of the references are listed.Bortezornib (velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer
Shahab Uddin et al.
CANCER RESEARCH (2008)
S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma
S. Uddin et al.
JOURNAL OF PATHOLOGY (2008)
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population
J. Abubaker et al.
ONCOGENE (2008)
Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas
Tint Lwin et al.
BLOOD (2007)
Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer
Gennaro Chiappetta et al.
ENDOCRINE-RELATED CANCER (2007)
The proteasome: A worthwhile target for the treatment of solid tumours?
Amalia Milano et al.
EUROPEAN JOURNAL OF CANCER (2007)
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
Frederik Holst et al.
NATURE GENETICS (2007)
Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells
Azhar R. Hussain et al.
CANCER RESEARCH (2007)
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib
Jiabin An et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival
Shahab Uddin et al.
BLOOD (2006)
NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model
James C. Cusack et al.
CLINICAL CANCER RESEARCH (2006)
Testing the importance of p27 degradation by the SCFskp2 oathwav in murine models of lung and colon cancer
Inke Timmerbeul et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: A tissue microarray analysis
Prashant Bavi et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo
T. A. Navas et al.
LEUKEMIA (2006)
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis
M Bazzaro et al.
CANCER RESEARCH (2006)
Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma
S Uddin et al.
ONCOGENE (2005)
The ubiquitin-proteasome pathway and its role in cancer
A Mani et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation
F Chen et al.
CELLULAR SIGNALLING (2005)
Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells
S Uddin et al.
CLINICAL CANCER RESEARCH (2005)
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)
D Yin et al.
ONCOGENE (2005)
Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma -: Relation to p27Kip1 and its ubiquitin ligase subunit, S phase kinase protein 2
M Shapira et al.
CANCER (2004)
Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells
H Ovaa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP)
HC Dan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells
S Uddin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
N-terminal ubiquitination of extracellular signal-regulated kinase 3 and p21 directs their degradation by the proteasome
P Coulombe et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Clinical update: proteasome inhibitors in hematologic malignancies
P Richardson
CANCER TREATMENT REVIEWS (2003)
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer
S Signoretti et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Proteasome inhibition in cancer: Development of PS-341
J Adams
SEMINARS IN ONCOLOGY (2001)
Apoptosis and its clinical impact
BR Gastman
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2001)
Skp2 is oncogenic and overexpressed in human cancers
M Gstaiger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI
D Soligo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27
D Ganoth et al.
NATURE CELL BIOLOGY (2001)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells
RC Gardner et al.
BIOCHEMICAL JOURNAL (2000)
Share Paper
